{"name":"Toni Choueiri, MD","slug":"toni-choueiri-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUm13cGVzZF9rZnZSbkh2MGVjSGwwU3hGOXN6X0FvRkFQeDgtR0lkZjYxd3lhcUF4ck1ZcDhsQmV2OGY2NDViaHhNTXpmY20zQzBFZXpwRk5GVE1HZU1BY01GSEJPSTgwUmlobnNyUGVIVDNtbk8zR1g2amJjZ2ZsZjhNVTZOTUNnZjdPWmJpVXZETTJETVJlUkptTmxTVzNpU0kxWS11OS0?oc=5","date":"2026-02-28","type":"pipeline","source":"Fierce Pharma","summary":"A new standard? Merck's Welireg combos deliver 1-2 punch to kidney cancer - Fierce Pharma","headline":"A new standard? Merck's Welireg combos deliver 1-2 punch to kidney cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdVA3eW02VG02RUYxdlNsbUJSRWI4N1R3dU9uYWFOelA3NGRuUm5EUEZjdzFTd0YyZnhieXRoOV9lcFctUG5UbDBFTEQtc05fblVxVlBrY2RJZDRiWThibmh3aGNuUU9uclM4bE9vS181VzA2ZFM4TFNRczNkN2ZISjJmdTZXQjhiSW5yNW90djFTMTJBVlIxMkl1bjB0S25TcVFxc2ljQlJWeUk?oc=5","date":"2025-02-06","type":"trial","source":"Fierce Biotech","summary":"Cancer vaccine prevents recurrence of advanced kidney cancer in small trial - Fierce Biotech","headline":"Cancer vaccine prevents recurrence of advanced kidney cancer in small trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxONFpMeTJYS0hRclBRSkRfSDViMlBCNXo4Y1Y5T2EzeVBOUVgwQTJKZTBkcFdDaHhYYmJTS0JOVU4ybENjSHJuLVFXYU94UEhmVGVDSnBrOXNmQVE1d3dsN3YwcUZmODVBaTVlN2JzVVFwVHVNT1Bzei03M2VnWTd5R2lwczFMWEhCclBiYWZraHRQVkNvajNnZHpBYjdCWmlkZy1KdzZfMDJtY3M?oc=5","date":"2024-07-18","type":"trial","source":"Fierce Pharma","summary":"Aveo spins a silver lining in failed trial of kidney cancer drug Fotivda - Fierce Pharma","headline":"Aveo spins a silver lining in failed trial of kidney cancer drug Fotivda","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOTnVZNmFvQ2c1RW4wam9nVHZaVENGQmpaWFc5Z0ptX0c2MUhmd2lvU3hnUHBURlA4Ylh2NDhkMl9TLVNtMm1BR0NLLUpNay1Fckh4b3U2VldldGxrbnFtRFhTRkYxdnlYOWJQeFpzdWNVMFRFMUVWTGI3Nkx2Q0g0LU82Ql9ucWlVZWl2S0dJTThyLWx5UHdEdmhGZkNZbTVFT2NPRU5KbXo4UWRIU1E?oc=5","date":"2024-01-10","type":"pipeline","source":"ASCO Daily News","summary":"Using Clinical Characteristics to Guide Treatment of Recurrent RCC After Adjuvant Pembrolizumab - ASCO Daily News","headline":"Using Clinical Characteristics to Guide Treatment of Recurrent RCC After Adjuvant Pembrolizumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUEUyMlNYRm43Y0g2SnJpZkU2MUNfcGVraG1PV2N4UVI3VFNjYTd0b2phRk4tQmhxUEdwMEpZakdZYU1vcjZEeW9FRXdQSkxwUVJnTkZvaEZxcDk3bnk0TlRwM1JxVUlJY1hhRFZqeGFoZUdaNC15TTVCdmlHdlFQaGZKcHdpWnNVU05uSFJBR2xqY3E5OEduSGxJQmRTSEtBUlFDeGM1eC1ic1FMVHdLZEF4R2RvWDBmY0VR?oc=5","date":"2023-08-10","type":"trial","source":"OncLive","summary":"SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC - OncLive","headline":"SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQeVZyS3VzX3JOU1Q0RDQwRXA0SC1LOXRPRXZwSTJjM3FZMWdJQmlIYTV4dEp3bTlYdndTM2lkR3VMaW5idnVudjlfMDNGbXpzNFJuRFpRMFd5N0xySUdVRXdLUXFHZVVEQ2dMei1TTGVwSkdRdkJBQmpIYlVlZEs3NkctOG5vT25MMWl6QTRJMmQyYzFYS29UVG0yNjlmaks5Zi1ueHgxTUEtYVdVY0tjTGNFS1VCNU5GS2c?oc=5","date":"2023-07-11","type":"trial","source":"OncLive","summary":"Negative Survival Data From CONTACT-03 Call ICI Rechallenge in Advanced RCC Into Question - OncLive","headline":"Negative Survival Data From CONTACT-03 Call ICI Rechallenge in Advanced RCC Into Question","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOX3Zod21tcTVxc2NOTXJCN1pFVXczVTlHOEV5MFpWeU9PdjM5QmF4cEJyMW9PVzRTTUtVa3hNa09uRURvWHIyOWZLeVdrTVNxUXI1VEh0bjlSdnM5NFdNa0ZRU3ltUExVem1RTXB0SWNiRm04TFZ5dFphdjhxeERvRkp6RWR5Y0xiSndnMFpiTDd2ZzU1ZFlPNldjVmFxOERkOFFPNG9OaTRiVklxQ0haNUJPWGJnQVRT?oc=5","date":"2022-07-11","type":"regulatory","source":"Fierce Pharma","summary":"Exelixis trots out combo win for Cabometyx and BMS meds in kidney cancer. Will the FDA get on board? - Fierce Pharma","headline":"Exelixis trots out combo win for Cabometyx and BMS meds in kidney cancer. Will the FDA get on board?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPVmxCTzhzY3E4bXFDQWhsSEN1OVZ1ZDRKUjgwdzBTR1BOWExoUHVDNXlGVE96d3NlTF9mNGFsUThQazJBSGdkMUthc056cUJsMnBsRlZqcDl5T2RuVnlqRUpKbTlwcGhaODBDbUhPUnFUdVdiU21Vb1dXTmlockY5MGd4Rnl2NG5yQ0hWajdtSENiNTZGXzhiRzRLZzBMX2FQTFBON1hhUXd0OXgtYzc3NGNEdGlpTnJ4VWRkVmtwTWdBVWM4YklzYXdQMTNyX01pN0l3aQ?oc=5","date":"2022-03-25","type":"pipeline","source":"The ASCO Post","summary":"KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma - The ASCO Post","headline":"KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQbGZpeTdpWHhqTmlmVjFVSnh4UXd3OHUxekJvdlBGQnUyYWw3Mmc0aVdpeXpKRXNKRkVrNmZrYkt4VlJXLTZKQ0t0TC0tUmJwWXlWQU1td21xM1FvN1RmNm8tTXVlZlhndjVveTV1SE5OQ1p3RWxBUHdoU09DMU1DdW1tM2FHMkltcGw1N1NJN1o5SlZ6WWY4amxyczljY1NqNWh5UEwzdG8wWUhSVHNjNUVVTVgzWVFnLWNFMA?oc=5","date":"2022-01-20","type":"pipeline","source":"ASCO Daily News","summary":"First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma: How to Choose Between Different Combinations - ASCO Daily News","headline":"First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma: How to Choose Between Different Combinations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOLVhiUmRpNFhna096cmM2TDhPcXI0Z1NpTWRTc1NURzVPWlZ5dHQ2R2E4elUtdGpZOC1RVGlKQ3FNSVk5X3MtX21HNmhINy01anNnUjIzazMtV1BHdVhuQXNXc0VIaThEUFljcFozTTR6c256eWs1YmMyRVJobUhkQk8wR0RwSlBkMXNMOXNSVzBSQ1ZDT0ttR1plbnpGeVhnQU9nUFk5bUx5emdnMmlmeUJjdGlwb3c?oc=5","date":"2021-10-06","type":"pipeline","source":"ASCO Daily News","summary":"Sexual and Gender-Based Harassment in Oncology: It's Not Just Time for Society to Heal—It's Time for Us to Change - ASCO Daily News","headline":"Sexual and Gender-Based Harassment in Oncology: It's Not Just Time for Society to Heal—It's Time for Us to Change","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQM2VTcUpydTZ1WFJaWWExTFdRWjhuVnQ4NTBjcnN1MklPSlZIMTJqS09EZmlxcGVoVkVJVDNKTkttakN2dTNCcnhVb0dUNHp1RlZNeUhGMFlraUs2NkxZeGloUFFrcE5hZ0hkWU9fQmtROHVVdmw5WldNWkRTcVBVejZYenU4cG1Rc2FqbTVOeE9DUWZzSElOV2VpSkE0QlVGdDE4enYtZk1TeHJMYVlBN2ZR?oc=5","date":"2021-02-11","type":"pipeline","source":"ASCO Daily News","summary":"Prescribing Immunotherapy As First-Line Treatment for Metastatic Renal Cell Carcinoma - ASCO Daily News","headline":"Prescribing Immunotherapy As First-Line Treatment for Metastatic Renal Cell Carcinoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBOVHBVTGRxd0JkUThHSjBrQzEtM3JoT0RDTUFDUkc1bkF2YWI1X3JKUy1oZzlFS3FnamF3bGlycDVLS0FEMk5WOWNYa0Yzenh2M2lPUFF4akJ6M01WSklJ?oc=5","date":"2018-04-05","type":"pipeline","source":"NEJM","summary":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma - NEJM","headline":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}